News
The company has reduced its general and administrative expenses by 14% and R&D expenses by 31% compared to Q1 2024, indicating effective cost management. Dare Bioscience Inc (NASDAQ:DARE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback